Feb
14
2015

Laser Therapy Going Beyond Skin Deep

There was an interesting workshop alongside of the A4M conference mid December 2014 organized by Jonathan Schwartz who gave an overview of the use of low-dose laser therapy for various clinical applications. It involved the use of the Dr. Michael Weber low-dose laser machine, which has a lot of versatility.

  1. First there are 5 laser light frequencies in the rainbow colors (infrared, red, yellow, green, blue) and the colors have very special characteristics as will be explained further below.
  2. There are a multitude of applicators like skin acupressure point applicators, a shower for hair loss applications, a head adapter, which looks like a crown. With this device red light will penetrate into the brain through the skull bone. There is also a mouth shower and various lengths needle applicators that can be used to access the body intravenously or interstitially (direct tissue approach). At the center of the equipment is the Weberneedle Compactlaser, which can be attached to the various applicators.

Laser characteristics

The blue laser penetrates about 1 cm (0.39 inch) under the skin, a green laser penetrates only 0.5 cm (0.19 inch); like the blue laser the yellow laser penetrates through the skin with a depth of 1 cm (0.39 inch). The red laser has a penetration depth of 2-3 cm (a bit more or less than 1 inch) and the infrared laser penetrates 5-7 cm (2 to 2 1/2 inches).

In addition the various lasers have different inherent qualities: The red laser is good for tissue regeneration, which lends itself for chronic pain. Green and blue lasers have anti-inflammatory effects, which helps in acute pain. The yellow laser can be used for detoxification, has antidepressant qualities and photosensitizes hypericin, a substance derived from St. John’s wort, which is known to have antidepressant qualities. The various types of laser mentioned can be used interstitially, intravenously and just on the skin surface over acupuncture points. Dr. Weber explained that detailed research has revealed that the low-dose energy beam sends out energy that is taken up by the surrounding tissues and cells. The mitochondria of the cells get activated to produce more ATP, which the cells use to heal themselves.

Meeting in Placentia

Forward to a meeting in Placentia, CA on Feb. 7, 2015 where Dr. Michael Weber and several other speakers gave presentations on the use of the Dr. Weber laser system. A number of local doctors who had an interest in learning more about the low-dose laser system were there as well. It was a daylong mini conference.

Three volunteers were used to demonstrate the use of the system. I was volunteering about a chronic left lower back pain that various chiropractors had problems adjusting in the past year. I have a strong family history of arthritis on my mother’s side and my maternal grandmother’s side as well. The health professionals thought that I likely have developed arthritis in the left sacro-iliac joint. Dr. Weber used the interstitial needle, which is 4 cm (1.57 inches) long. The skin was injected with a local anesthetic first, and then the needle was inserted, which I could hardly feel. Now he injected 5 cc of normal saline. This was used, so that the laser light would spreads more into the surrounding area. Dr. Weber explained that he was very close to the SI joint with the tip of the needle on the left. He attached a blue laser to it for 20 minutes and switched it to a green laser for another 20 minutes.

In the meantime the other two volunteers were treated.

One was a physician in the group who had a chronic planter’s fasciitis. He was treated with an intravenous laser application. First a special butterfly was inserted, through which a sterile laser probe could be threaded and then attached. He received a red laser.

The third volunteer had a chronic right knee problem from congenital Osgood Schlatter disease. In him Dr. Weber used an approach of intraarticular injection and he attached a blue laser for 20 minutes, followed by a yellow laser for another 20 minutes. A physician with a California license supervised all of these procedures.

I woke up the following day with no pain in my left lower back, but at the same time the lesser right lower back pain had also disappeared. I figure that due to the fact that my back mobility is back the untreated right side must have normalized as well. It is now 7 days following the procedure and I still have no back pain. Yesterday I saw my local chiropractor in Southern California and he confirmed that my back was much easier to adjust than the month before (Update April 12, 2015: my lower back is still pain free!).

Normally a case like mine would require 5 to 6 weekly treatments before the problem is resolved. Dr. Weber explained that more complicated problems like fibromyalgia would take 15 to 20 treatments in succession or more. The principal is always that you treat where the symptoms are; in the follow-up visit the healthcare practitioner treats the remaining symptoms until all of the symptoms have resolved.

The intriguing fact is that low-dose laser therapy seems to fit right into gap where conventional medicine has failed.

Clinical cases that respond to laser therapy

Dr. Weber has collected clinical cases that improve with laser treatments, such as diabetes, chronic liver diseases, chronic pain syndromes, rheumatoid arthritis, polyneuropathy, chronic inflammatory disease, cancer (with photodynamic therapy), fibromyalgia, high blood pressure, ringing in the ears (tinnitus), macular degeneration, multiple sclerosis, chronic fatigue syndrome, Lyme disease, allergies and eczema. This, however, is just a partial list.

Photodynamic cancer therapy is made possible by the fact that certain substances have absorption spectra that are activated by different wavelength. This amplifies the effect of the natural substance that is used by several folds. For instance Chlorin E6 absorbs a red laser (around 660 nm). A blue laser activates Curcumin. A yellow laser activates Hypericin. Here is a website that explains the principle of phototherapy.

Various cancers can be treated where conventional medicine has so far failed. Examples are lymph metastases from breast cancer, pancreatic cancer, and bladder cancer. I have blogged regarding a combination treatment for breast cancer before, where phototherapy with lasers and immunostimulation were combined. Esophageal cancer is treated through esophagoscopy combined with a laser that activates curcumin, which had been taken orally well before the procedure. Not all of the cases are successful, but the majority of them are.

Otherwise routine low-dose laser applications are used for tendinitis, tennis elbow, sprains and soft tissue injures.

Laser-Therapy-Going-Beyond-Skin-Deep

Laser-Therapy-Going-Beyond-Skin-Deep

You can combine the laser system with prolotherapy. Prolotherapy is done first by injecting hyperosmolar dextrose solution, which is a strong stimulator of stem cells. Using the same needle, but attaching the Weber low-level laser therapy will activate the stem cells and protect them from dying off.

Conclusion

Low dose laser therapy using the Weber Medical technology is a new treatment modality available to the interested physician. I think that it will cause a revolution within medicine. It is scientifically sound and it fits right into the difficult to treat patients; the patients that otherwise would be unlikely to respond. However, they will respond well to these new treatment modalities. Apart from musculoskeletal problems, various cancers will also respond to this. The Mayo clinic is starting a study on treating cancer using phototherapy and the Dr. Weber low-dose laser system.

Mar
01
2004

Inflammatory Marker Linked To Blindness

This outline is about “inflammatory marker linked to blindness”. Up to now age-related blindness or “age-related macular degeneration” (AMD) as it is medically called, has been a mystery. Notably, the retina is the light-sensitive area of the eye similar to the film in a camera. Specifically, the “macula” is that part of the retina that has the highest visual acuity. It is important to realize that several studies have been conducted lately regarding age-related blindness. Most compelling evidence sheds more light on this important health hazard of old age. One day these studies might even lead to a cure or powerful preventative measures to avoid AMD from ever developing.

Macular degeneration related to C-reactive protein

Particularly, one such study is the one by Dr. Johanna M. Seddon and co-workers published in the Feb. 11, 2004 issue of the Journal of the American Medical Association. Almost 1000 patients with various degrees of age-related degrees of blindness from the Age-Related Eye Disease Study (AREDS) were classified by the degree of their macular degeneration. As an illustration, I have produced the bar graphs below based on these studies.

Details of AMD in relation to CRP

For one thing, the researchers defined four groups, namely those with no AMD who served as controls. The second group were those with mild AMD, the third group those with moderate AMD. And the fourth group were those with severe AMD who were legally blind. Specifically, they suspected that an inflammatory marker in the blood stream of these patients, called C-reactive protein (CRP), might be present in the more severe cases of blindness when compared to the control group who did not have any inflammatory changes in the macula. Indeed, the bar graphs below show exactly what the test results indicated. Another key point, they also found that smokers (blue bars) tended to have slightly worse blood tests in terms of CRP (more inflammatory substances circulating in the system) within the same severity category of the age-related eye changes.

CRP (mg/L) Levels in Various Degrees of Severity of Age-related Macular Degeneration (AMD)

Inflammatory Marker Linked To Blindness

Inflammatory Marker Linked To Blindness

Risk of AMD depends on value of CRP

The investigators studied the risk for the highest percentile of the CRP tests within various subgroups of AMD. They found several differences as shown in the next table. First there was a low probability to develop AMD in a person with a normal looking macula. The investigators took this risk as the 1.0 point for comparison. In contrast a person with a normal looking macula who smokes has a 1.5-fold risk of developing AMD later. Patients with a moderate degree of AMD have about a 2-fold risk of getting a severe degree of AMD. This is true for smokers and non-smokers. Once the inflammatory cycle has started, the process of causing a moderate degree of AMD is so strong. This means that the effect of smoking will not add that much in comparison.

This is the first study of this kind that established that CRP is useful as a screening for the risk to develop AMD. Physicians already use CRP  as a test for monitoring progress in rheumatoid arthritis or to monitor for the risk of developing a heart attack or stroke.

AMD risk studied by another research group

Another study by Dr. Johanna M. Seddon and co-workers was published recently in the Archives of Ophthalmology. 261 people aged 60 years and older with established AMD were followed for 4.6 years and checked for deterioration. 101 patients had deterioration of their AMD.

Risk of Developing Age-Related Macular Degeneration (AMD) in Highest CRP Percentile
 Inflammatory Marker Linked To Blindness1

Omega-3 fatty acids protect against AMD

The authors analyzed the patients’ diet habits and found that increased fat intake was a high risk factor for deteriorating AMD. Both vegetable and animal fat had a 2-to 3-fold increased risk for deterioration of the AMD to a more severe stage (legal blindness). Fish, omega-3 fatty acid and nuts had a protective effect, but only when omega-6 fatty acid (linoleic acid) intake was low in the same group. The studies showed that the risk of age-related blindness was reduced by 40% when patients ate nuts at least once per week. The authors concluded that a “fat conscious diet” would be good for “maintaining good eye health” and at the same time be beneficial for prevention of heart attacks and strokes.

The authors will do further studies to investigate potential ways of helping patients with AMD and to understand the mechanisms of the disease process better.

References

1. JAMA 2004;291:704-710  2. Arch Ophthalmol – 01-DEC-2003; 121(12): 1728-37